Quinolones

Antimicrobial Pharmacodynamics in Theory and Clinical Practice, Second Edition

Volumn , Issue , 2007, Pages 177-188

  Ambrose, Paul G ^a,b   Bhavnani, Sujata M ^a   Owens, Robert C ^c  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010921455     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (30)

1. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
2. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 1997; 26:1-12.
3. Craig WA. Pharmacodynamics of antimicrobials: general concepts and application. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel-Dekker, 2002:1-21.
4. Andes DR, Craig WA. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 1998; 27:47-50.
5. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacody-namics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Che-mother 1993; 37:1073-1081.
6. Forrest A, Chodash S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chermother 1997; 40(suppl A):45-57.
7. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1997; 279:125-129.
8. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacody-namics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45: 2793-2797.
9. Booker BM, Smith PF, Forrest A, et al. Application of an in vitro infection model and simulation for re-evaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother 2005; 49:1775-1781.
10. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-1060.
11. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-490.
12. Lacy MA, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43:672-677.
13. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43:79-86.
14. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin, and sparflox-acin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. J Antimicrob Chemother 2001; 47:811-818.
15. Lister PD. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 2002; 46:69-74.
16. Eagle H. Effect of schedule of administration on therapeutic efficacy of penicillin: importance of aggregate time penicillin remains at effectively bactericidal levels. Am J Med 1950; 9:280-299.
17. Eagle H, Fleischman R, Mussleman AD. Effective concentrations of penicillin in vitro and in vivo for streptococci and pneumococci and Treponema. J Bacteriol 1950; 59:625-643.
18. Eagle H, Fleischman R, Levy M. Continuous versus discontinuous therapy with penicillin: effect of interval between injections on therapeutic efficacy. N Engl J Med 1953; 248:481-488.
19. Craig WA. Does dose matter? Clin Infect Dis 2001; 33(suppl 3):S233-S237.
20. Craig WA, Andes DA. Correlation of the magnitude of the AUC24/MIC for 6 fluoroquinolones against Streptococcus pneumoniae with survival and bactericidal activity in an animal model [abstr 289]. Abstracts of the 40th Interscience Conference of Antimicrobial Chemotherapy. Toronto, Canada: 2000.
21. Leggett JE, Ebert S, Fantin B, et al. Comparative dose-effect relations several dosing intervals for beta-lactam, aminoglycoside, and quinolone antibiotics against Gramnegative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1991; 74:179-184.
22. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone AUC: MIC ratio and the probability of eradication of the infecting pathogen in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-1597.
23. Dony Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44:2581-2584.
24. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 2001; 29:251-256.
25. Blondeau JM, Zhao X, Hansen G, Karl Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-438.
26. Tam VH, Louie A, Deziel MR, et al. Pharmacokinetics of BMS-284756 in counter-selecting resistance in a hollow-fiber system [abstr A-442]. Abstracts of the 41st Interscience Conference of Antimicrobial Chemotherapy. Chicago, Illinois: 2001.
27. Tam VH, Louie A, Deziel MR, Liu W, Grasela DM, Miller MH, Drusano GL. Pharmacokinetics of BMS-284756 and ciprofloxacin against Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber system. [abstract A-443] In: Abstracts of the 41st Interscience Conference of Antimicrobial Chemotherapy. Chicago, Illinois: 2001.
28. Fazili T, Louie A, Tam V, Deziel M, Liu W, Drusano GL. Effect of innoculum on the pharmacodynamic breakpoint dosage that prevents selection of gatifloxacin resistance in ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae [abstr A-445]. Abstracts of the 41st Interscience Conference of Antimicrobial Chemotherapy. Chicago, Illinois: 2001.
29. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275-285.
30. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-527.